Breast cancer surveillance following ovarian cancer in BRCA mutation carriers

CONCLUSIONS: Ten percent of women developed BC after EOC. The incidence of BC following EOC in BRCA carriers increases over time, and surveillance is recommended given their enhanced survival of EOC. Timely genetic testing for women with EOC is imperative to better triage BC screening resources and treatment.PMID:34862065 | DOI:10.1016/j.ygyno.2021.10.077
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

Immune checkpoint inhibitors can be effective in patients with non-small cell lung cancer and mild interstitial lung disease, but with a greater risk.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Pulmonary Medicine News Source Type: news
AbstractPurposeGenetic variants may influence the pharmacokinetics and pharmacodynamics (PKPD) of cyclophosphamide (CY). CY plays a critical role in conditioning chemotherapy for hematopoietic cell transplantation (HCT), but its use is limited by toxicity. We explored the effect of genetic variants, potentially affecting PKPD of CY, and outcomes after HCT.MethodsThis observational pharmacogenomic study included 85 adults with hematologic malignancies who received reduced intensity conditioning with CY, fludarabine, and total body irradiation. We collected recipient DNA prior to HCT and evaluated 97 candidate variants in 66...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Oncogene, Published online: 27 January 2022; doi:10.1038/s41388-021-02158-wSELENOF is a new tumor suppressor in breast cancer
Source: Oncogene - Category: Cancer & Oncology Authors: Source Type: research
Dalton Trans., 2022, Accepted Manuscript DOI: 10.1039/D1DT04315C, PaperXiang Wang, Kang Song, Yong Deng, Jie Liu, Qin Peng, Xiao Lao, Jiayu Xu, Dong Wang, Turong Shi, Yuhao Li, Dan Deng, Yuqing Miao Photodynamic therapy (PDT) is an effective non-invasive treatment for tumors. The structure of the photosensitizer has an important influence on the light utilization and the efficiency of singlet-oxygen generation. In... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Dalton Trans. latest articles - Category: Chemistry Authors: Source Type: research
Chem. Commun., 2022, Advance Article DOI: 10.1039/D1CC06330H, CommunicationXiao-Jie Dong, Wen-Yan Li, Qun Guan, Yan-An Li, Yu-Bin Dong A COF-based multifunctional nanomedicine CuS@COF-BDP, which can be used as a PTT/PDT bimodal therapeutic agent to inhibit cancer cell proliferation under visible- and NIR-II-light irradiation, is reported. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - Category: Chemistry Authors: Source Type: research
ConclusionsDecompression using a SEMS as the BTS may improve oncological outcomes over those achieved by a TDT in patients with left-sided stage II and III OCRC.
Source: Surgery Today - Category: Surgery Source Type: research
AbstractPurposePrevious studies have reported that sarcopenia increases the risk of postoperative complications following colorectal resection. This retrospective study assessed the postoperative complications of rectal resection associated with sarcopenia.MethodsWe retrospectively analyzed 262 patients who underwent curative low anterior resection for primary rectal cancer from January 2008 to May 2020 at our institution. The patients were divided into a sarcopenia group (normalized total psoas muscle area  
Source: Surgery Today - Category: Surgery Source Type: research
Conclusion MTDH is pro-oncogenic factor playing multifaceted and diverse roles in cancer progression. Its association and central role in regulating signaling pathways such a MAPK, wnt/β-catenin, PI3K/AkT, NF-κβ pathways in various cancers shows that it plays a vital role in metastasis. MTDH contribution to chemo and radiotherapy resistance provides a new direction for the development of anticancer therapeutics. Multiple mechanisms converge to promote expression of MTDH in cancers. Further studies are therefore warranted to determine whether the elevated MTDH expression has prognostic value for development...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, our WGCNA analysis identified candidate prognostic biomarkers for further basic and clinical researches. Introduction Breast cancer is a frequently diagnosed malignancy and the leading cause of cancer death among females around the world, accounting for 24% of cancer diagnoses and 15% of cancer deaths in females. According to Global Cancer Statistics 2018, there will be nearly 2.1 million new cases diagnosed globally, with ~62 thousand deaths. The incident rates of breast cancer increased in most developing countries during last decades, resulting from a combination of social and economic factors, incl...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: Elafin predicts poor outcome in breast and ovarian cancer patients delineates a subset of endocrine receptor positive breast cancer patients susceptible to recurrence whom could benefit from more aggressive intervention. Our in vitro results suggest that elafin arrests cell luminal breast cancer cells, perhaps suggesting a role in tumor dormancy.
Source: Breast Cancer Research - Category: Cancer & Oncology Authors: Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Epithelial Cancer | Genetics | Mammography | Mastectomy | Ovarian Cancer | Ovaries | Statistics | Women